GenFleet Therapeutics (Shanghai) Inc. (2595)

Overview

GenFleet Therapeutics (Shanghai) Inc. is a clinical-stage biotechnology company that specializes in creating innovative therapies for oncology and immunology. Established in 2017 and headquartered in Shanghai, GenFleet is dedicated to addressing significant unmet medical needs by focusing on first-in-class drug candidates, particularly for various solid tumors and autoimmune diseases. The company sets itself apart through a proprietary and fully integrated research and development platform that supports a comprehensive pipeline of both small molecule and biologic therapies utilizing novel mechanisms of action.

Among GenFleet's notable achievements is the development of Dupert® (fulzerasib), which is recognized as the first approved KRAS G12C inhibitor in China and the third globally. This milestone underscores the company's advanced capabilities in targeted cancer therapies. GenFleet is also committed to building a robust portfolio that not only addresses current medical challenges but also enhances the landscape of precision medicine within the biopharmaceutical industry through global research collaborations and commercial partnerships.

Products and Services

• Dupert® (fulzerasib)

  Dupert® is the first approved KRAS G12C inhibitor in China and the third globally, representing a breakthrough in targeted cancer treatment. This therapy is designed to effectively target specific genetic mutations that drive the growth of certain cancers, providing patients with a novel treatment option for solid tumors.

• GFH375

  GFH375 is currently under global clinical evaluation for the treatment of non-small cell lung cancer (NSCLC). This product demonstrates GenFleet's commitment to developing cutting-edge therapies aimed at improving outcomes for patients battling one of the most challenging forms of cancer.

• Research and Development Platform

  GenFleet operates a fully integrated research and development platform that facilitates the discovery, development, and commercialization of both small molecule and biologic therapeutic candidates. This platform is crucial for supporting the company's pipeline and ensuring a streamlined process from concept to clinical trials.

• Global Collaborations and Partnerships

  The company actively pursues global research collaborations and commercial partnerships that amplify its market presence and facilitate the development of its innovative therapies. These strategic alliances are essential in advancing GenFleet's mission to transform precision medicine and tackle significant health challenges globally.